venous thromboembolism prophylaxis
Cardiovascular · 2009–2009
Every decision here pre-dates the consumer comments facility, so no input would be recorded either way.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| dabigatran etexilate mesilate Prevention of venous thromboembolic events in adult patients undergoing total hip replacement (THR) and total knee replacement (TKR). | Nov 2009 | Recommended with restriction | no section in document |
Appraised elsewhere
NICE, in England and Wales, has appraised 2 technologies for this condition, recommending 2 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 0 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.